TFS Capital’s Agile Therapeutics AGRX Stock Holding History

TFS Capital’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-20	Closed	-$223K	–	902
2016 Q4	$223K	Buy	20 +15	+300%	+$210K	0.06%	491
2016 Q3	$73K	Sell	5 -6	-55%	-$85.6K	0.02%	690
2016 Q2	$164K	Buy	+11	New	+$151K	0.03%	775

Other funds holding AGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TFS Capital's AGRX Position: Q1 2017 in Review

TFS Capital sold out of Agile Therapeutics (AGRX) in Q1 2017, closing a stake of 20 shares — an estimated $223K sold.

TFS Capital first reported a position in AGRX in Q2 2016 and held it in 3 quarters. The position peaked at $223K in Q4 2016. 48 funds tracked by Wall St. Rank hold AGRX as of Q1 2017.

TFS Capital reported no remaining Agile Therapeutics position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 20 Agile Therapeutics shares in Q1 2017, an estimated $223K.
TFS Capital first reported a position in Agile Therapeutics in Q2 2016 and held it in 3 quarters.
TFS Capital's Agile Therapeutics position peaked at $223K in Q4 2016.
48 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.